Autres langues LigaChem Biosciences Inc.

Actions

A141080

KR7141080002

Cours en clôture Korea S.E. Autres places de cotation 00:00:00 03/06/2024			Varia. 5j.	Varia. 1 janv.
66 000 ^KRW	+3,61 %		+3,94 %	+1,54 %

16/05	Biosciences LigaChem Inc. rapporte ses résultats pour le premier trimestre terminé le 31 mars 2024	CI
08/04	NextCure, Inc. et LigaChem Biosciences, Inc. présentent des données précliniques sur le conjugué anticorps-médicament B7-H4 à l'AACR 2024	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

LigaChem Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05
NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024	08/04
Pan Orion Corp. Ltd. completed the acquisition of 4.93% stake in LegoChem Biosciences, Inc. from Kim Yong Ju and Park Se Jin.	29/03
LigaChem Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Samsung Biologics Collaborates with LegoChem Biosciences on ADC Development and Manufacturing	09/02
South Korean Shares Close Lower Amid Geopolitical Tension	16/01
J&J : accord de licence avec le coréen LegoChem dans les ADC	27/12
Legochem Biosciences Announces License Agreement for Lcb84 Trop2-Targeted ADC	26/12
LegoChem Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
BostonGene and LegoChem Biosciences, Inc. Announce Collaboration to Support Phase I/II Study of LCB84, TROP2-Directed ADC, in Patients with Advanced Cancers	07/11
LegoChem Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/08/23
LegoChem Biosciences, Inc. announces an Equity Buyback for KRW 5,000 million worth of its shares.	28/06/23
LegoChem Biosciences, Inc. authorizes a Buyback Plan.	28/06/23
LegoChem Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23
LegoChem Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23/03/23
Legochem Biosciences and Amgen Enter into A Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates	23/12/22
NextCure, Inc. and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug Conjugates	15/11/22
HBM Holdings Limited Announces Commenced Collaborations on Antibody-Drug Conjugate Projects with Legochem Biosciences Inc. and Duality Biotherapeutics	30/05/22
Iksuda Therapeutics Announces Further Expansion of ADC Pipeline Through Licensing Agreement with Legochem Biosciences	10/01/22
LEGO : 1 milliards de dollars de bénéfice trimestriel, loin devant Hasbro	29/09/21

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues LigaChem Biosciences Inc.

Actions

A141080

KR7141080002

Autres langues

Filtres